Tafolecimab clinical trials
Tafolecimab is named as an intervention in 11 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is China National Center for Cardiovascular Diseases (1). The most-studied condition is PCSK9 Inhibitor.
How Tafolecimab works
All drug targets →- Subtilisin/kexin type 9 inhibitor InhibitorTarget: PCSK9 proprotein convertase subtilisin/kexin type 9✓ In ChEMBL and the Guide to Pharmacology
- Combined hyperlipidemiaPhase 3
- HypercholesterolemiaPhase 3
- Familial hypercholesterolemiaPhase 3
- Non-small cell lung carcinomaPhase 2
- Rectal cancerPhase 2
- Small cell lung carcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4594554, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12517, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Tafolecimab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Tafolecimab
11 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Tafolecimab
23 conditionsAll 23 conditions
| Condition (as registered) | Trials |
|---|---|
| PCSK9 Inhibitor | 2 |
| Acute Coronary Syndrome | 1 |
| Non ST Segment Elevation Acute Coronary Syndrome | 1 |
| Lipid Lowering, Vascular Inflammation | 1 |
| Lung Cancer | 1 |
| Gastric Adenocarcinoma | 1 |
| Esophagogastric Juction Cancer | 1 |
| Proficient Mismatch Repair | 1 |
| Bladder Urothelial Carcinoma | 1 |
| Bladder Cancer | 1 |
| Acute Myocardial Infarction (AMI) | 1 |
| Hyperlipidemia | 1 |
| Colon Cancer | 1 |
| Neoadjuvant Immunochemotherapy | 1 |
| Local Advanced Rectal Cancer | 1 |
| PD-1 Inhibitor | 1 |
| RCT | 1 |
| Ischemic Stroke or High-risk TIA (ABCD² ≥ 4) | 1 |
| Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 1 |
| Extensive Stage Lung Small Cell Cancer | 1 |
| Extensive-Stage Small-Cell Lung Cancer | 1 |
| Extensive Disease Small Cell Lung Cancer | 1 |
| Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 11 | 5 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Tafolecimab trials
How many clinical trials are testing Tafolecimab?
11 current trials in our China register name Tafolecimab (also registered as IBI306) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Tafolecimab trials recruiting patients?
Yes. 5 of the 11 trials are recruiting: 5 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Tafolecimab clinical trials?
China National Center for Cardiovascular Diseases (1), Jinghui Wang (1), First Affiliated Hospital of Zhejiang University (1) and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1), among 11 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tafolecimab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tafolecimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tafolecimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.